Efficacy of Adding Sodium Hyaluronate Eye Drops to Tobramycin and Dexamethasone in the Treatment of Post-Cataract Surgery Dry Eye Disease: A Retrospective Analysis and Prospective Questionnaire Assessment

Figures & data

Table 1 Pretreatment and Post Treatment Data of the Examined Patients

		Group A (n = 70)	Group B (n = 73)	p-value
Age (years): Mean ± SD		60.97 ± 6.75	60.27 ± 6.33	0.262^a
Sex: N (%)	Male	42 (60%)	44 (60.3%)	0.262^b
	Female	28 (40%)	29 (39.7%)
Smoking: N (%)		8 (11.4)	11 (15.1%)	0.521^c
TBUT: Mean ± SD	Pretreatment	3.8 ± 1.37	3.96 ± 1.58	0.522^a
	Post treatment	7.53 ± 1.58	9.19 ± 1.39	< 0.001*^a
	p-value	< 0.001*^d	< 0.001*^d
Schirmer I: Mean ± SD	Pretreatment	6.6 ± 1.97	6.41 ± 2.05	0.287^a
	Post treatment	10.1 ± 3	12.75 ± 2.29	< 0.001*^a
	p-value	< 0.001*^d	< 0.001*^d
FS: Median (IQR)	Pretreatment	2 (2–2)	2 (2–3)	0.231^e
	Post treatment	1 (0–1)	0 (0–0)	< 0.001*^e
	p-value	< 0.001*^f	< 0.001*^f
Duration between treatment and OSDI assessment: Mean ± SD (months)		18.3 ± 7.31	17.2 ± 6.89	0.178^a
OSDI: Mean ± SD		15.78 ± 5.85	11.27 ± 3.59	< 0.001*^a
Overall efficacy: N (%)	Cure	1 (1.4%)	26 (35.6%)	< 0.001*^b
	High effectiveness	13 (18.6%)	31 (42.5%)
	Effectiveness	52 (74.3%)	16 (21.9%)
	Ineffectiveness	4 (5.7%)	0 (0%)

Notes: ^aIndependent t-test, ^bChi-square test, ^cZ test for proportion, ^dPaired t-test, ^eMann–Whitney test, ^fWilcoxon signed ranks test, *Statistically significant.

Abbreviations: OSDI, ocular surface disease index; TBUT, tear break-up time; FS, fluorescein corneal staining, IQR, interquartile range, SD, standard deviation.

Figure 1 Pretreatment and Post treatment TBUT values in the study groups.

Figure 2 Pretreatment and Post treatment Schirmer I values in the study groups.

Figure 3 Pretreatment and Post treatment FS scores in the study groups.

Figure 4 Post treatment OSDI values in the study groups.